Maraviroc: a new CCR5 antagonist

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• HIV-1 entry into CD4 cells typically requires binding to CD4 and a coreceptor, either CXCR4 or CCR5.
• Maraviroc represents a novel class of antiretroviral agents, CCR5 antagonists, targeting a specific step in the HIV lifecycle.
• The US FDA approved maraviroc in August 2007 for treatment-experienced adults with CCR5-tropic HIV-1 infection and viral replication.

Purpose of the Study:

• To evaluate the efficacy and safety of maraviroc as a CCR5 antagonist in HIV-1 treatment.
• To assess the ability of maraviroc to prevent HIV entry by blocking the CCR5 coreceptor.
• To highlight maraviroc's role in managing HIV infection when other therapies are insufficient.

Main Methods:

• Maraviroc functions by blocking the CCR5 coreceptor, thereby preventing R5-tropic HIV-1 from entering uninfected CD4 cells.
• The study involved treatment-experienced adult patients with CCR5-tropic HIV-1 and evidence of viral replication.
• Dosing recommendations consider potential drug interactions, with available formulations of 150-mg and 300-mg tablets.

Main Results:

• Maraviroc demonstrated the ability to achieve undetectable HIV-1 RNA levels in clinically advanced patients.
• The drug was effective in patients with evidence of viral replication despite ongoing antiretroviral therapy.
• Maraviroc is generally well tolerated and does not exhibit cross-resistance with existing antiretroviral therapies.

Conclusions:

• Maraviroc is a valuable new therapeutic option for specific patient populations with HIV-1 infection.
• Its mechanism of action, targeting CCR5, offers a novel approach to HIV treatment.
• The development of maraviroc addresses the urgent need for new antiretroviral agents with distinct mechanisms.